Summary

Location
at UCSF
Dates
study started
completion around

Description

Summary

An extension of Global Phase III open-label, multicenter designed to evaluate the Long-term safety and efficacy of study drug for the treatment of the MPS II.

Keywords

Mucopolysaccharidosis II, Mucopolysaccharidoses, JR-141 2.0 mg/kg/week

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland
    Oakland California 94609 United States
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre Brazil
  • Instituto de Genética e Erros Inatos do Metabolismo
    São Paulo Brazil

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
JCR Pharmaceuticals Co., Ltd.
ID
NCT05594992
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 80 study participants
Last Updated